

MEDICAL POLICY

POLICY TITLE	PROTEOGENOMIC TESTING FOR PATIENTS WITH CANCER
POLICY NUMBER	MP - 2.343

Original Issue Date (Created):	2/1/2017
Most Recent Review Date (Revised):	6/22/2020
Effective Date:	9/1/2020

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Proteogenomic testing (see Policy Guidelines section) of patients with cancer (including but not limited to GPS Cancer™ test) is considered **investigational** for all indications as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Policy Guidelines

Proteogenomic testing involves the integration of proteomic, transcriptomic, and genomic information. *Proteogenomic* testing can be differentiated from *proteomic* testing, in that *proteomic* testing can refer to the measurement of protein products alone, without integration of genomic and transcriptomic information. When protein products alone are tested, this is not considered proteogenomic testing.

Genetics Nomenclature Update

Human Genome Variation Society (HGVS) nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical policies updates starting in 2017 (see Table PG1). The Society’s nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) standards and guidelines for interpretation of sequence variants represent expert opinion from ACMG, AMP, and the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.

MEDICAL POLICY

POLICY TITLE	PROTEOGENOMIC TESTING FOR PATIENTS WITH CANCER
POLICY NUMBER	MP - 2.343

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Diseased-Assoc.Variant	Disease-associated change in the DNA sequence.
	Variant	Change in DNA sequence
	Familial Variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives.

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely Pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

(ACMG) American College of Medical Genetics and Genomics; AMP: Association of Molecular Pathology.

Genetic Counseling

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital BlueCross. Please see additional information below, and subject to benefit variations as discussed in Section VI below.

FEP PPO- Refer to FEP Medical Policy Manual MP-2.04.140, Proteogenomic Testing for Patients with Cancer. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

POLICY TITLE	PROTEOGENOMIC TESTING FOR PATIENTS WITH CANCER
POLICY NUMBER	MP - 2.343

III. DESCRIPTION/BACKGROUND

[TOP](#)

Proteogenomics

The term proteome refers to the entire complement of proteins produced by an organism or cellular system, and proteomics refers to the large-scale comprehensive study of a specific proteome. Similarly, the term transcriptome refers to the entire complement of transcription products (messenger RNAs), and transcriptomics refers to the study of a specific transcriptome. *Proteogenomics* refers to the integration of genomic information with proteomic and transcriptomic information to provide a more complete picture of the function of the genome.

A system’s proteome is related to its genome and genomic alterations. However, while the genome is relatively static over time, the proteome is more dynamic and may vary over time and/or in response to selected stressors. Proteins undergo a number of modifications as part of normal physiologic processes. Following protein translation, modifications occur by splicing events, alternative folding mechanisms, and incorporation into larger complexes and signaling networks. These modifications are linked to protein function and result in functional differences that occur by location and over time

Some of the main potential applications of proteogenomics in medicine include:

- Identifying biomarkers for diagnostic, prognostic, and predictive purposes
- Detecting cancer by proteomic profiles or “signatures”
- Quantitating levels of proteins and monitoring levels over time for:
- Cancer activity
- Early identification of resistance to targeted tumor therapy
- Correlating protein profiles with disease states.

Proteogenomics is an extremely complex field due to the intricacies of protein architecture and function, the many potential proteomic targets that can be measured, and the numerous testing methods used. Types of targets currently being investigated and the testing methods used and under development next are discussed briefly herein.

Proteomic Targets

A proteomic target can be any altered protein that results from a genetic variant. Protein alterations can result from germline and somatic genetic variants. Altered protein products include mutated proteins, fusion proteins, alternative splice variants, noncoding messenger Rs, and posttranslational modifications (PTMs).

Mutated Protein (Sequence Alterations)

A mutated protein has an altered amino acid sequence that arises from a genetic variant. A single amino acid may be replaced in a protein or multiple amino acids in the sequence may be affected. Mutated proteins can arise from germline or somatic genetic variants. Somatic variants can be differentiated from germline variants by comparison with normal and diseased tissue.

MEDICAL POLICY

POLICY TITLE	PROTEOGENOMIC TESTING FOR PATIENTS WITH CANCER
POLICY NUMBER	MP - 2.343

Fusion Proteins

Fusion proteins are the product of one or more genes that fuse together. Most fusion genes discovered have been oncogenic, and fusion genes have been shown to have clinical relevance in a variety of cancers.

Alternative Splice Events

Posttranslational enzymatic splicing of proteins results in numerous protein isoforms. Alternative splicing events can lead to abnormal protein isoforms with altered function. Some alternative splicing events have been associated with tumor-specific variants.

Noncoding RNAs

Noncoding portions of the genome serve as the template for noncoding RNA (ncRNA), which plays various roles in the regulation of gene expression. There are 2 classes of ncRNA: shorter ncRNAs, which include microRs and related transcript products, and longer ncRNAs, which are thought to be involved in cancer progression.

Posttranslational Modifications

PTMs of histone proteins occur in normal cells and are genetically regulated. Histone proteins are found in the nuclei and play a role in gene regulation by structuring the D into nucleosomes. A nucleosome is composed of a histone protein core surrounded by D. Nucleosomes are assembled into chromatin fibers composed of multiple nucleosomes assembled in a specific pattern. PTMs of histone proteins include a variety of mechanisms, including methylation, acetylation, phosphorylation, glycosylation, and related modifications.

Proteogenomic Testing Methods

Proteogenomic testing involves isolating, separating, and characterizing proteins from biologic samples, followed by correlation with genomic and transcriptomic data. Isolation of proteins is accomplished by trypsin digestion and solubilization. The soluble mix of protein isolates is then separated into individual proteins. This is generally done in multiple stages using high-performance liquid chromatography ion-exchange chromatography, Dimensional gel electrophoresis, and related methods. Once individual proteins are obtained, they may be characterized using various methods and parameters, some of which we describe below. There is literature addressing the analytic validity of these testing techniques.

Immunohistochemistry and Fluorescence in situ Hybridization

Immunohistochemistry (IHC) and fluorescence in situ hybridization are standard techniques for isolating and characterizing proteins. IHC identifies proteins by using specific antibodies that bind to the protein. Therefore, this technique can only be used for known proteins and protein variants because it relies on the availability of a specific antibody. This technique also can only test a relatively small number of samples at once.

There are a number of reasons why IHC and fluorescence in situ hybridization are not well-suited for large-scale proteomic research. They are semiquantitative techniques and involve subjective interpretation. They are considered low-throughput assays that are time-consuming

MEDICAL POLICY

POLICY TITLE	PROTEOGENOMIC TESTING FOR PATIENTS WITH CANCER
POLICY NUMBER	MP - 2.343

and expensive and require a relatively large tissue sample. Some advances in IHC and fluorescence in situ hybridization have addressed these limitations, including tissue microarray and reverse phase protein array.

- Tissue microarrays can be constructed that enable simultaneous analysis of up to 1000 tissue samples.
- Reverse phase protein array, a variation on tissue microarrays, allows for a large number of proteins to be quantitated simultaneously.

Mass Spectrometry

Mass spectrometry (MS) separates molecules by their mass to charge ratio and has been used as a research tool for studying proteins for many years. 1 Development of technology that led to the application of MS to biologic samples has advanced the field of proteogenomics rapidly. However, the application of MS to clinical medicine is in its formative stages. There are currently several types of mass spectrometers and a lack of standardization in the testing methods. Additionally, MS equipment is expensive and currently largely restricted to tertiary research centers.

The potential utility of MS lies in its ability to provide a wide range of proteomic information efficiently, including:

- Identification of altered proteins;
- Delineation of protein or peptide profiles for a given tissue sample;
- Amino acid sequencing of proteins or peptides;
- Quantitation of protein levels;
- 3-dimensional protein structure and architecture; and
- Identification of PTMs.

MS Sampling Applications

“Top-down” MS refers to identification and characterization of all proteins in a sample without prior knowledge of which proteins are present. This method provides a profile of all proteins in a system, including documentation of PTMs and other protein isoforms. This method, therefore, provides a protein “profile” or “map” of a specific system. Following initial analysis, intact proteins can be isolated and further analyzed to determine amino acid sequences and related information.

“Bottom-up” MS refers to the identification of known proteins in a sample. This method identifies peptide fragments that indicate the presence of a specific protein. This method depends on having peptide fragments that can reliably identify a specific protein. Selective reaction monitoring MS is a bottom-up modification of MS that allows for direct quantification and specific identification of low-abundance proteins without the need for specific antibodies. This method requires the selection of a peptide fragment or “signature” that is used to target the specific protein. Multiplex assays have also been developed to quantitate the epidermal growth factor receptor, human epidermal growth factor receptors 2 and 3, and insulin-like growth factor-1 receptor.

MEDICAL POLICY

POLICY TITLE	PROTEOGENOMIC TESTING FOR PATIENTS WITH CANCER
POLICY NUMBER	MP - 2.343

Bioinformatics

Due to the complexity of proteomic information, the multiple tests used, and the need to integrate this information with other genomic data, a bioinformatics approach is necessary to interpret proteogenomic data. Software programs integrate and assist in the interpretation of the vast amounts of data generated by proteogenomics research. One software platform that integrates genomic and proteomic information is PARADIGM, which is used by The Cancer Genome Atlas (TCGA) project for data analysis. Other software tools currently available include:

- The Genome Peptide Finder matches the amino acid sequence of peptides predicted de novo with the genome sequence.
- The Proteogenomic Mapping Tool is an academic software for mapping peptides to the genome.
- Peppy is an automated search tool that generates proteogenomic data from translated databases and integrates this information for analysis.
- VESPA is a software tool that integrates data from various platforms and provides a visual display of integrated data.

Ongoing Proteogenomic Database Projects

There are also networks of researchers coordinating their activities in this field. The Clinical Proteomic Tumor Analysis Consortium is a coordinated project among sites sponsored by the National Cancer Institute. This project seeks to characterize the genomic and transcriptomic profiles of common cancers systematically. Consortium has cataloged proteomic information for several types of cancers including breast, colon, and ovarian cancers. All project data are freely available.

Many existing genomic databases have begun to incorporate proteomic information. TCGA intends to profile changes in the genomes of 33 different cancers. As part of its analysis, messenger R expression is used to help define signaling pathways that are either upregulated or deregulated in conjunction with genetic variations. Currently, TCGA has published comprehensive molecular characterizations of multiple cancers, including breast, colorectal lung, gliomas, renal, and endometrial cancers.

GPS Cancer Test

The GPS Cancer test is a commercially available proteogenomic test intended for patients with cancer. The test includes whole-genome sequencing (20,000 genes, 3 billion base pairs), whole transcriptome (RNA) sequencing, and quantitative proteomics by mass spectrometry. The test is intended to inform personalized treatment decisions for cancer, and treatment options are listed when available, although treatment recommendations are not made. Treatment options may include U.S. Food and Drug Administration–approved targeted drugs with potential for clinical benefit, active clinical trials of drugs with potential for clinical benefit, and/or available drugs to which the cancer may be resistant.

MEDICAL POLICY

POLICY TITLE	PROTEOGENOMIC TESTING FOR PATIENTS WITH CANCER
POLICY NUMBER	MP - 2.343

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Act. The GPS Cancer™ test (NantHealth, Culver City, CA) is available under the auspices of Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

IV. RATIONALE

[TOP](#)

Summary of Evidence

For individuals who have cancer and indications for genetic testing who receive proteogenomic testing (eg., GPS Cancer test), the evidence includes cross-sectional studies that correlate results with standard testing and that report comprehensive molecular characterization of various cancers, and cohort studies that use proteogenomic markers to predict outcomes and that follow quantitative levels over time. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, and treatment-related mortality and morbidity. There is no published evidence on the clinical validity or utility of the GPS Cancer test. For proteogenomic testing in general, the research is at an early stage. Very few studies have used proteogenomic tumor markers for diagnosis or prognosis, and at least 1 study has reported following quantitative protein levels for surveillance purposes. Further research is needed to standardize and validate proteogenomic testing methods. Once standardized and validated testing methods are available, the clinical validity and utility of proteogenomic testing can be adequately evaluated. The evidence is insufficient to determine the effect of the technology on health outcomes.

V. DEFINITIONS

[TOP](#)

N/A

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits and which require preauthorization. There are different benefit plan designs in each product administered by Capital BlueCross. Members and providers should consult the member's health benefit plan for information or contact Capital BlueCross for benefit information.

MEDICAL POLICY

POLICY TITLE	PROTEOGENOMIC TESTING FOR PATIENTS WITH CANCER
POLICY NUMBER	MP - 2.343

VII. DISCLAIMER

[TOP](#)

Capital BlueCross’s medical policies are developed to assist in administering a member’s benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member’s benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member’s plan of benefits, please contact Capital BlueCross’ Provider Services or Member Services. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Proteogenomic testing of patients with cancer (including but not limited to GPS Cancer™ test) is considered investigational for all indications; therefore, not covered:

CPT Codes®								
81479								

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

IX. REFERENCES

[TOP](#)

1. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. Jul 18 2012;487(7407):330-337. PMID 22810696
2. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature*. Oct 4 2012;490(7418):61-70. PMID 23000897
3. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. *N Engl J Med*. Jun 25 2015; 372(26):2481-2498. PMID 26061751
4. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. *Nature*. May 2 2013;497(7447):67-73. PMID 23636398
5. Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. *N Engl J Med*. Jan 14 2016;374(2):135-145. PMID 26536169

POLICY TITLE	PROTEOGENOMIC TESTING FOR PATIENTS WITH CANCER
POLICY NUMBER	MP - 2.343

6. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. Jul 31 2014;511(7511):543-550. PMID 25079552
7. Catenacci DV, Liao WL, Thyparambil S, et al. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. *PLoS One*. Jul 1 2014;9(7):e100586. PMID 24983965
8. Catenacci DV, Liao WL, Zhao L, et al. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. *Gastric Cancer*. Oct 2016;19(4):1066-1079. PMID 26581548
9. Center for Strategic Scientific Initiatives. CPTAC Data Portal Overview. 2018; <https://cptac-data-portal.georgetown.edu/cptacPublic/>. Accessed June 22, 2020.
10. Chang Gung Bioinformatics Center. Cancer Mutant Proteome Database. 2014; <https://pdfs.semanticscholar.org/4a26/844dde304ffacc2132c99c157c8557782114.pdf/>. Accessed June 22, 2020..
11. Edwards NJ, Oberti M, Thangudu RR, et al. The CPTAC Data Portal: a resource for cancer proteomics research. *J Proteome Res*. Jun 5 2015;14(6):2707-2713. PMID 25873244
12. Geneffects. Peppy - proteogenomic, proteomic search tool. 2012; <http://www.geneffects.com/peppy>. Accessed June 22, 2020.
13. Gregorich ZR, Ge Y. Top-down proteomics in health and disease: challenges and opportunities. *Proteomics*. May 2014;14(10):1195-1210. PMID 24723472
14. Hembrough T, Thyparambil S, Liao WL, et al. Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. *J Mol Diagn*. Jul 2013;15(4):454-465. PMID 23672976
15. Huang PJ, Lee CC, Tan BC, et al. CMPD: cancer mutant proteome database. *Nucleic Acids Res*. Jan 2015;43(D1):D849-855. PMID 25398898
16. Hudler P, Videtic Paska A, Komel R. Contemporary proteomic strategies for clinical epigenetic research and potential impact for the clinic. *Expert Rev Proteomics*. Apr 2015;12(2):197-212. PMID 25719543
17. Keshava Prasad TS, Goel R, Kandasamy K, et al. Human Protein Reference Database--2009 update. *Nucleic Acids Res*. Jan 2009;37(Suppl 1):D767-772. PMID 18988627
18. Latonen L, Afyounian E, Jylha A, et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. *Nat Commun*. Mar 21 2018;9(1):1176. PMID 29563510
19. Li J, Duncan DT, Zhang B. CanProVar: a human cancer proteome variation database. *Hum Mutat*. Mar 2010;31(3):219-228. PMID 20052754
20. NantHealth. GPS Cancer. n.d.; <http://nanthealth.com/gps-cancer/>. Accessed June 22, 2020.
21. National Cancer Institute OoCCPR. Background. n.d.; <https://proteomics.cancer.gov/proteomics/background> Accessed June 22, 2020..
22. Pandey Lab and Institute of Bioinformatics. Human Protein Reference Database. n.d.; <http://www.hprd.org/>. Accessed June 22, 2020.

MEDICAL POLICY

POLICY TITLE	PROTEOGENOMIC TESTING FOR PATIENTS WITH CANCER
POLICY NUMBER	MP - 2.343

23. Rudnick PA, Markey SP, Roth J, et al. A description of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) common data analysis pipeline. *J Proteome Res.* Mar 04 2016;15(3):1023-1032. PMID 26860878
24. Sanders WS, Wang N, Bridges SM, et al. The proteogenomic mapping tool. *BMC Bioinformatics.* Apr 22 2011;12:115. PMID 21513508
25. Sellappan S, Blackler A, Liao WL, et al. Therapeutically induced changes in HER2, HER3, and EGFR protein expression for treatment guidance. *J Natl Compr Canc Netw.* May 2016;14(5):503-507. PMID 27160229
26. Specht M. *Genomic Peptide Finder.* 2012; <http://specht.github.io/gpf/>. Accessed June 22, 2020.
27. Subbannayya Y, Pinto SM, Gowda H, et al. Proteogenomics for understanding oncology: recent advances and future prospects. *Expert Rev Proteomics.* Mar 2016;13(3):297-308. PMID 26697917
28. Yau C, Meyer L, Benz S, et al. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index. *Breast Cancer Res Treat.* Nov 2015;154(1):23-32. PMID 26456572
29. Blue Cross Blue Shield Association Medical Policy Reference Manual. 2.04.140 Proteogenomic Testing for Patients with Cancer, June 13, 2019.

X. POLICY HISTORY

[TOP](#)

MP 2.343	CAC 7/27/16 New policy. Proteogenomic testing of patients with cancer (including but not limited to GPS Cancer™ test) is considered investigational for all indications. Coding added.
	3/01/17 Administrative change. FEP variation added.
	CAC 11/28/17 Consensus review. Policy statement unchanged. Description/Background, Rationale and Reference sections updated. Coding reviewed.
	8/23/18 Consensus review. No change to the policy statement. Policy revised with updated genetics nomenclature. Policy title shortened to “Proteogenomic Testing for Patients with Cancer”. Background, and references updated. Rationale revised. 2/19/19 Code review completed, no changes.
	7/15/19 Consensus review. No change to the policy statement. Tables and references updated.
	6/22/2020: Consensus review. No change to policy statement. Coding reviewed with no changes. References reviewed and updated. Product variation statement updated.

[Top](#)

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.